Peer-reviewed veterinary case report
Effect of the Aβ aggregation modulator MRZ-99030 on retinal damage in an animal model of glaucoma.
- Journal:
- Neurotoxicity research
- Year:
- 2014
- Authors:
- Salt, T E et al.
- Affiliation:
- UCL Institute of Ophthalmology · United Kingdom
- Species:
- rodent
Abstract
Several lines of evidence suggest that there are similarities in the pathomechanisms of glaucoma and Alzheimer's disease, and that amyloid-beta (Aβ) could be a new, promising target for neuroprotective therapy of glaucoma. In the present study, we evaluated the effect of the Aβ aggregation modulator MRZ-99030 in the Morrison model of glaucoma based on increased intraocular pressure (IOP) in rats. MRZ-99030 provided dose-dependent neuroprotection and at the highest dose (240 mg/kg) reduced the degree of RGC apoptosis to 33 % of that seen after vehicle (P < 0.05; one-way ANOVA). No significant effect on IOP was observed. Pharmacokinetic experiments showed that following systemic injection of MRZ-99030, concentrations above affinity for Aβ were reached. Hence the present results are consistent with the notion that Aβ is a promising target for neuroprotective intervention in glaucoma and that MRZ-99030 may be a good drug candidate for further development.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication: https://pubmed.ncbi.nlm.nih.gov/25106883/